Saturday, September 23, 2023
Saturday, September 23, 2023

iApotheca Healthcare Inc. Announces Closing of $470K Angel Funding Round

iApotheca Healthcare, the developers of a leading Canadian pharmacy software operations platform, has announced the closing of a $470k angel funding round. iApotheca will use the funds to accelerate their EconoRoute™ Prescription Delivery System through the addition of key team members, ongoing platform development and the expansion of the EconoRoute™ network.

“Prescription delivery is revolutionizing the way people interact with their chosen pharmacy,” said Spencer Turbitt, co-founder and CEO of iApotheca. “We would like to thank Leva Capital, York Angels, and Valhalla Angels for their investment in our company. Their investment and advice are allowing us to accelerate our plans to achieve our vision for the pharmacy delivery space.”

iApotheca specializes in streamlining pharmacy operations, particularly in prescription delivery service, to help pharmacies grow their revenue. In recent years, the demand for prescription delivery has seen a sharp rise. iApotheca’s EconoRoute™ prescription delivery software supports the demand with an easy-to-use, low-cost, one-stop solution for pharmacies of all sizes.

“Leva Capital is thrilled to announce the addition of iApotheca into our investment portfolio,” said Eddie Gobran, Managing Partner. “Their strategy aligns with our vision of investing in health technology that will improve the healthcare experience for Canadians. We are confident in iApotheca’s team to execute their strategy and deliver a great experience to pharmacies across Canada.”

EconoRoute™ includes features that make it an ideal delivery solution for any business. Its unique physics-based instant routing and real-time driver tracking are high-performance tools. Built-in pay-at-the-door functionality also makes it easy for businesses to track accounting.

iApotheca’s years of expertise in supporting pharmacies in doing business more efficiently make EconoRoute™ more than just another prescription delivery service.  The software has the added benefit of built-in compliance tools, cold-chain prioritization, and inherent patient privacy measures, all crucial for compliance. Taken together, these tools make EconoRoute™ a must-have for prescription delivery.

“Willowgrove Pharmacy has been using EconoRoute™ since its inception. After spending much time researching delivery platforms, EconoRoute™ came out the clear winner,” said Devon Elias, owner of Willowgrove Pharmacy in Manitoba. “The application does everything we need it to do. Optimization of routes, easy set up of regular repeat deliveries, tracking and signature requirements are all in one application, allowing for a single program to be our delivery central. Willowgrove Pharmacy employs three full-time positions for delivery of product and services and EconoRoute™ easily organizes it all.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Lipogems® Announces 140 Independent Peer Reviewed Publications with 5 Years of Follow up in Orthopaedics

Giorgio Ninzoli, President of Lipogems International. "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."

Study Outcomes Could Provide Insights Into New Targeted Treatments to Manage this Challenging Disease

The study aims to determine if immediate biological preservation of patient-derived chordoma tumor tissue, collected intraoperatively and implanted for serial sampling in translational research, will provide new insights into the biological weakness of the disease and contribute to developing improved treatment therapies reports NICO.

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Utilizing Lunit INSIGHT MMG, an FDA-cleared and CE-marked AI solution for mammography analysis, this research backs AI's potential to replace one human reader under Europe's double reading guideline and underscores its capacity to alleviate the strain on radiologists.

MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study

SELUTION DeNovo Study is the largest DEB study ever initiated, involving up to 70 participating sites across 15 countries. Patients are randomized before any vessel preparation to reflect current medical practice and to reduce bias.  The objectives of the study are to demonstrate non-inferiority at both one and five years, and superiority for target vessel failure (TVF) at five years.

Vitestro Starts Largest-scale Clinical Trial Globally for its Autonomous Blood Drawing Device, with Enrolment of First Patients in A.D.O.P.T.

Vitestro expects to obtain CE marking by the end of 2024. The first 350 patients have currently been enrolled the A.D.O.P.T. (Autonomous Optimization and Performance Tests for Blood Testing) Trial at study site Result Laboratorium in the Albert Schweitzer Hospital. Investigational partners, in addition to Result Laboratorium - Albert Schweitzer Hospital, are St. Antonius, OLVG Lab and Amsterdam UMC.

By using this website you agree to accept Medical Device News Magazine Privacy Policy